Cyclerion Therapeutics

Historical price data

Cyclerion Therapeutics has strategically pivoted from its prior sGC focus to become a neuropsychiatric-focused company developing personalized, device-enabled therapeutics. Its lead candidate, CYC-126, targets treatment-resistant depression (TRD) by aiming to 'reset' dysregulated brainwave patterns, representing a convergence of pharmacotherapy and digital health. Under the leadership of CEO Regina Graul, PhD, and supported by a board with deep CNS and biotech expertise, the company is building a pipeline intended to transform care in areas of significant unmet medical need. Cyclerion is publicly traded (NASDAQ: CYCN) and has recently announced a definitive merger agreement with Korsana Biosciences.

A personalized neuromodulation platform combining well-characterized anesthetic agents with a proprietary biofeedback-driven device system designed to 'reset' dysregulated brainwave patterns in neuropsychiatric disorders.